DIABETIC KIDNEY DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On March 05, 2024, Novo Nordisk, a multinational pharmaceutical company announced the results from the kidney outcomes trial FLOW. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD). In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials.
• In February 2023, The European Commission approved a label extension for Kerendia (finerenone) in the European Union (EU) that includes cardiovascular (CV) outcomes from the Phase III FIGARO-DKD research. The study found that Kerendia lowered the risk of cardiovascular events in a large sample of patients with CKD stages 1-4 and T2D. Kerendia is currently recommended for the treatment of chronic kidney disease (albuminuria) in individuals with type 2 diabetes.
• In January 2023, Boehringer Ingelheim, a pharmaceutical company, and Eli Lilly and Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which are being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD)
• In April 2021, AstraZeneca, a global pharmaceutical company, announced that Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had been approved in the U.S. by FDA to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and heart failure hospitalization (hHF) in adults with CKD at risk of progression